{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.0","upperLimit":"61.2","value":"55.2"},{"groupId":"OG001","lowerLimit":"20.6","upperLimit":"30.9","value":"25.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"290"}],"units":"Participants"}],"title":"PD-L1 Positive Tumors"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.2","upperLimit":"55.8","value":"47.0"},{"groupId":"OG001","lowerLimit":"20.5","upperLimit":"37.3","value":"28.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"120"}],"units":"Participants"}],"title":"PD-L1 Negative Tumors"}],"denoms":[{"counts":[{"groupId":"OG000","value":"402"},{"groupId":"OG001","value":"410"}],"units":"Participants"}],"description":"OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"NUMBER","populationDescription":"Biomarker positive/negative subset in FAS included participants who had at least one biomarker baseline assessment. Here \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. \"Number Analyzed\" signifies number of participants evaluable for the specified rows.","reportingStatus":"POSTED","timeFrame":"From date of randomization until PD (maximum up to approximately 26 months)","title":"Percentage of Participants With OR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}